Aclaris therapeutics announces patent license agreement with sun pharma for alopecia

Wayne, pa., dec. 05, 2023 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with sun pharmaceutical industries, inc. (sun pharma).

ACRS Ratings Summary

ACRS Quant Ranking